ChemoCentryx ContactKeep Me PostedSite Map
Medicines in MotionChemoCentryx is a clinical stage focused pharmaceutical company creating small molecule medicines for autoimmune diseases, inflammatory disorders and oncology.
Announcement
ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur of the Year 2010 Award Finalist in Northern California
ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference
  More News >
GET MORE information about ChemoCentryx's products. LEARN ABOUT chemokines and diseases. FIND OUT about clinical trials of Traficet-EN™ for IBD.
GET MORE information about ChemoCentryx's products. LEARN ABOUT chemokines and diseases. FIND OUT about clinical trials of Traficet-EN for IBD.

© 2010 ChemoCentryx, Inc. Legal | Site User's Guide